Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Commitment to spend, operational expenses, initial lease term Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term Payments as a percentage of net sales Revenue Interest Purchase Agreement, Payments, Percentage Of Net Sales Revenue Interest Purchase Agreement, Payments, Percentage Of Net Sales Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Statistical Measurement Statistical Measurement [Domain] Title of 12(b) Security Title of 12(b) Security Net loss attributable to ImmunityBio common stockholders Net Income (Loss) Available to Common Stockholders, Diluted Subsequent Event Subsequent Event [Member] Schedule Of Available For Sale Securities [Table] Debt Securities, Available-for-Sale [Table] Document Fiscal Year Focus Document Fiscal Year Focus Commissions Adjustments to Additional Paid in Capital, Stock Issued, Commissions Adjustments to Additional Paid in Capital, Stock Issued, Commissions Adjustment to Compensation, Amount Adjustment to Compensation Amount Long-Term Debt [Roll Forward] Long-Term Debt [Roll Forward] Long-Term Debt Financial Instrument Financial Instrument [Axis] Number of Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Customer [Axis] Customer [Axis] Segment Reporting [Abstract] Realized gain on instrument-specific credit risk Realized Gain (Loss) On Instrument-Specific Credit Risk Realized Gain (Loss) On Instrument-Specific Credit Risk Common Stock, $0.0001 par value; 1,650,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 1,053,221,645 and 1,011,800,008 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; excluding treasury stock, 163,800 shares outstanding as of June 30, 2026 and December 31, 2025 Common Stock, Value, Issued 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Net share settlement for RSUs vesting Payment, Tax Withholding, Share-Based Payment Arrangement Derivative liabilities Embedded derivative liability Embedded Derivative, Fair Value of Embedded Derivative Liability ATM Offering Program At The Market Offering Program [Member] At-The-Market offering program. Lease Arrangements Lessee, Finance Leases [Text Block] Restatement Determination Date Restatement Determination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] 2027 Finance Lease, Liability, to be Paid, Year One Revenue Interest Purchase Agreement Revenue Interest Purchase Agreement [Member] Revenue Interest Purchase Agreement 2026 (excluding the six months ended June 30, 2026) Lessee, Lease Liability, to be Paid, Remainder of Fiscal Year Lessee, Lease Liability, to be Paid, Remainder of Fiscal Year Vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Amendment Flag Amendment Flag LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities, Current [Abstract] Thereafter Lessee, Lease Liability, to be Paid, After Year Five Lessee, Lease Liability, to be Paid, After Year Five Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Initial measurement of warrants issued in connection with equity offerings accounted for as liabilities Issuance Of Warrants Issuance Of Warrants Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Principal payments of finance leases Financing cash flow from finance leases Finance Lease, Principal Payments Class of Warrant or Right [Table] Class of Warrant or Right [Table] Stock option purchase liability Stock Option Purchase Liability, Fair Value Disclosure Stock Option Purchase Liability, Fair Value Disclosure Warrant Liabilities Warrant Liabilities [Text Block] Warrant Liabilities Long-term inventories, net Inventory, Noncurrent 2015 Share Repurchase Plan Two Thousand Fifteen Share Repurchase Plan [Member] 2015 share repurchase plan. Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Change in fair value of warrant liabilities Change in fair value of warrant liabilities Fair Value Adjustment of Warrants Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Financial Instruments Investment [Text Block] Revenue increase (decrease), gross-to-net accruals Revenue from Contract with Customer, Increase (Decrease) Related to Gross-to-Net Accruals Revenue from Contract with Customer, Increase (Decrease) Related to Gross-to-Net Accruals Purchase agreement milestone, received Purchase Agreement Milestone, Received Purchase Agreement Milestone, Received Leases [Abstract] Leases [Abstract] Other comprehensive (loss) income, net of income taxes: Other Comprehensive Income (Loss), Net of Tax [Abstract] Fair Value, Stock Purchase Option, Revenue Interest Purchase Agreement Fair Value, Stock Purchase Option, Revenue Interest Purchase Agreement [Member] Fair Value, Stock Purchase Option, Revenue Interest Purchase Agreement July 2025 Warrants July 2025 Warrant [Member] July 2025 Warrant Related-Party Debt Related-Party Agreements Related Party Transactions Disclosure [Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross PEO Total Compensation Amount PEO Total Compensation Amount Maximum milestone payment due if certain conditions are met Business Combination, Contingent Consideration, Change in Range of Outcomes, Liability, Maximum, Increase (Decrease) Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Asset Acquisition [Axis] Asset Acquisition [Axis] Nonvested, beginning balance (in units) Nonvested, ending balance (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Weighted-average number of common shares used in computing net loss per share – basic (in shares) Weighted-average number of common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Accretion of discounts on marketable debt securities, available-for-sale Accretion (Amortization) of Discounts and Premiums, Investments Allowance for inventory reserve Inventory Valuation Reserves Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Class of Warrant or Right, Outstanding [Roll Forward] Class of Warrant or Right, Outstanding [Roll Forward] Class of Warrant or Right, Outstanding Option to purchase, amount Lease, Operating Lease, Option To Purchase, Amount Lease, Operating Lease, Option To Purchase, Amount Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four Work-in-progress Inventory, Work in Process, Net of Reserves Warrant exercises (in shares) Number of warrants exercised (in shares) Class of Warrant or Right, Exercised Class of Warrant or Right, Exercised Altor Stockholders Altor Stockholders [Member] Altor Stockholders Entity Address, City or Town Entity Address, City or Town Pending Litigation Pending Litigation [Member] Granted (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Vested (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Product revenue, net Product [Member] 2030 Lessee, Lease Liability, to be Paid, Year Four Lessee, Lease Liability, to be Paid, Year Four Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount $505 Million Promissory Note, December 2023, Tranche 2 $505 Million Promissory Note, December 2023, Tranche 2 [Member] $505 Million Promissory Note, December 2023, Tranche 2 Net loss attributable to ImmunityBio common stockholders Net Income (Loss) Available to Common Stockholders, Basic 2025 Equity Incentive Plan Equity Incentive Plan, 2025 [Member] Equity Incentive Plan, 2025 Level 2 Fair Value, Inputs, Level 2 [Member] Other income (expense), net Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Total other comprehensive (loss) income Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Revenue Benchmark Revenue Benchmark [Member] U.S. UNITED STATES Purchase agreement milestone Purchase Agreement Milestone Purchase Agreement Milestone Subsequent Event Type [Axis] Subsequent Event Type [Axis] Vesting of RSUs (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Concentration Risk Type [Axis] Concentration Risk Type [Axis] Stock-based compensation expense capitalized into inventory Share-Based Payment Arrangement, Amount Capitalized Commissions and offering costs Adjustments to Additional Paid in Capital, Stock Issued, Commissions And Issuance Costs Adjustments to Additional Paid in Capital, Stock Issued, Commissions And Issuance Costs Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Litigation Case [Axis] Litigation Case [Axis] Property and equipment purchases included in accounts payable, accrued expenses and due to related parties Capital Expenditures Incurred but Not yet Paid Noncontrolling Interests Noncontrolling Interest [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Related-Party Related and Nonrelated Parties [Axis] Schedule of Changes in Carrying Amount of Warrant Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Shared Services Agreement Shared Services Agreement [Member] Shared services agreement. Payable and Accruals [Axis] Payable and Accruals [Axis] Payable and Accruals Exercise price of warrants (in dollars per share) Exercise price of warrants exercised (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Carrying value of debt Total Long-Term Debt Conversion to common stock Decrease in Fair Value, Conversion of Debt Decrease in Fair Value, Conversion of Debt Altor BioScience Corporation Altor BioScience, LLC [Member] Altor BioScience Corporation. Summary of Future Minimum Lease Payments, Operating Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Document Period End Date Document Period End Date Fourth Largest Customer Fourth Largest Customer [Member] Fourth Largest Customer Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Forfeited/expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Face amount Debt Instrument, Face Amount Net loss per ImmunityBio common share – basic and diluted Earnings Per Share, Basic [Abstract] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Stockholders’ Deficit Equity [Text Block] Security Exchange Name Security Exchange Name Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Potential contingent value rights to be earned Contingent Value Rights Obligations Contingent value rights obligations. Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Weighted average remaining lease term, finance leases Finance Lease, Weighted Average Remaining Lease Term Total liabilities measured at fair value Liabilities, Fair Value Disclosure Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Operating lease liabilities Operating lease liabilities (including amounts with related parties) Operating Lease, Liability, Current Ownership percentage acquired Percentage Of Wholly Owned Subsidiary Percentage of wholly-owned subsidiary. More than 12 months, Estimated Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Finance lease assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Earnings Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Proceeds from sales of marketable debt securities, available-for-sale Proceeds from Sale and Maturity of Marketable Securities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Revenue interest liability Revenue interest liability, beginning balance Revenue interest liability, ending balance Secured Long-Term Debt, Noncurrent Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Summary of Supplemental Balance Sheet Information Related to Leases Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Geographical Geographical [Domain] Summary of Interest Expense Interest Income and Interest Expense Disclosure [Table Text Block] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Unrecognized compensation cost related to unvested stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount 12 to 18 Months From Closing Date Period Two [Member] Period Two Company Selected Measure Name Company Selected Measure Name Sale of Stock Sale of Stock [Domain] Transaction Transaction [Domain] Purchases of marketable debt securities, available-for-sale Payments to Acquire Debt Securities, Available-for-Sale Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Business Combination, Contingent Consideration, Type Business Combination, Contingent Consideration, Type [Axis] Non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Cash paid for other equity securities Cash paid for securities Payments to Acquire Other Investments Change in fair value of derivative liabilities Change in Fair Value of Derivative Liabilities Change in Fair Value of Derivative Liabilities Principal Amount Long-Term Debt, Gross Later Than 36 Months from Closing Date Period Four [Member] Period Four Total lease assets (including amounts with related parties) Lease, Right-Of-Use Asset Lease, Right-Of-Use Asset Warrant liabilities Warrant Liabilities, Fair Value Disclosure Warrant Liabilities, Fair Value Disclosure Related Party Transactions [Abstract] Related Party Transactions [Abstract] Operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Due from related parties Other Receivables, Net, Current VivaBioCell VivaBioCell [Member] VivaBioCell. Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Outstanding third-party warrants Warrant [Member] Weighted-average number of common shares used in computing net loss per share – diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] 2028 Finance Lease, Liability, to be Paid, Year Two Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Tiered Payments [Domain] Tiered Payments [Domain] Tiered Payments [Domain] 2030 Finance Lease, Liability, to be Paid, Year Four U.S. Treasury securities US Treasury Securities [Member] Long-Term Debt, Fair Value Disclosure [Roll Forward] Long-Term Debt, Fair Value Disclosure [Roll Forward] Long-Term Debt, Fair Value Disclosure Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] February And July 2023 Warrants February And July 2023 Warrants [Member] February And July 2023 Warrants Prepaid expenses Prepaid Expense Other assets Increase (Decrease) in Other Noncurrent Assets Gross profit Gross Profit Revenue from Contract with Customer [Abstract] Less: Interest Finance Lease, Liability, Undiscounted Excess Amount Measurement input Embedded Derivative Liability, Measurement Input Cash paid for operating leases (excluding variable lease costs) Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Payable and Accruals [Domain] Payable and Accruals [Domain] Payable and Accruals [Domain] Aggregate intrinsic value of stock options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Schedule Of Available For Sale Securities [Line Items] Debt Securities, Available-for-Sale [Line Items] Altor BioScience Corporation Altor BioScience Corporation [Member] Altor BioScience Corporation. Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Proceeds from exercises of warrants Proceeds from Warrant Exercises Exercise price per share Measurement Input, Exercise Price [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Litigation Status [Domain] Litigation Status [Domain] Nonvested, beginning balance (in dollars per share) Nonvested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Number of square foot of facility leased Number Of Square Feet Of Facility Leased Number of square feet of facility leased. All Executive Categories All Executive Categories [Member] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Fair value, beginning balance Fair value, ending balance Long-Term Debt, Fair Value Embedded Derivative Financial Instruments Embedded Derivative Financial Instruments [Member] Plan Name Plan Name [Domain] Third Largest Customer Third Largest Customer [Member] Third Largest Customer Antidilutive Securities Antidilutive Securities [Axis] Scenario [Domain] Scenario [Domain] Asset Acquisition [Domain] Asset Acquisition [Domain] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Reconciliation of cash and cash equivalents, and restricted cash, end of period: Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Operating lease right-of-use assets, net Operating lease assets (including amounts with related parties) Operating Lease, Right-of-Use Asset Concentration Risk Type [Domain] Concentration Risk Type [Domain] Optional extended lease term Lessee, Operating Lease, Renewal Term Schedule of Basic and Diluted Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Segment Information Segment Reporting [Text Block] Proceeds from maturities of marketable debt securities, available-for-sale Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Minimum Minimum Minimum [Member] July 2023 Warrants July 2023 Warrants [Member] July 2023 Warrants Expiration Date Trading Arrangement Expiration Date Summary of Disaggregated Revenue Disaggregation of Revenue [Table Text Block] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Income Statement Location Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total stockholders’ deficit Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Non-related Party Nonrelated Party [Member] Related-party convertible note payable at fair value Amount Convertible Debt, Fair Value Disclosures Affiliated Entity Affiliated Entity [Member] Business Combination [Line Items] Business Combination [Line Items] Offering costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Proceeds from equity offerings, net of issuance costs Proceeds from Issuance of Common Stock Revenue interest purchase agreement, payment received percentage Revenue Interest Purchase Agreement, Payment Received Percentage Revenue Interest Purchase Agreement, Payment Received Percentage Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Percentage of sales agent commission Percentage Of Sales Agent Commission Percentage Of Sales Agent Commission Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Exercise of warrants Stock Issued During Period, Value, Warrants Exercised Stock Issued During Period, Value, Warrants Exercised Exercise Price Award Exercise Price Investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Related Party Transaction Related Party Transaction [Axis] Litigation Status [Axis] Litigation Status [Axis] Segment Reporting [Line Items] Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Europe Europe [Member] Cash and cash equivalents, and restricted cash, beginning of period Cash and cash equivalents, and restricted cash, end of period Cash and cash equivalents, and restricted cash, end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Effect of exchange rate changes on cash and cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Revenue Interest Purchase Agreement Debt Disclosure [Text Block] Periodic license payments, annual Collaboration Agreements, Periodic License Payments Collaboration Agreements, Periodic License Payments Scenario [Axis] Scenario [Axis] Commercial milestone commitments Contractual Obligation Other research and development costs Research and Development Expense, Internal, Other Costs Research and Development Expense, Internal, Other Costs Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Schedule Of Business Acquisitions By Acquisition [Table] Business Combination [Table] Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount July 2025 Warrant July 2025 Warrants [Member] July 2025 Warrants Measurement Input Type [Domain] Measurement Input Type [Domain] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] 2027 Lessee, Lease Liability, to be Paid, Year One Lessee, Lease Liability, to be Paid, Year One License Agreement Terms License Agreement Terms [Member] Sale of stock issued in transaction Sale of Stock, Consideration Received on Transaction Embedded contingent derivative liability related to Second Payment Embedded contingent derivative liability related to Third Payment Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Total operating costs and expenses Costs and Expenses Adoption Date Trading Arrangement Adoption Date Valuation Technique, Binomial Lattice Model Valuation Technique, Binomial Lattice Model [Member] Valuation Technique, Binomial Lattice Model Weighted average discount rate, finance leases Finance Lease, Weighted Average Discount Rate, Percent Counterparty Name [Domain] Counterparty Name [Domain] Total ImmunityBio stockholders’ deficit Equity, Attributable to Parent SRS/Altor Shareholder CVR Arbitration SRS/Altor Shareholder CVR Arbitration [Member] SRS/Altor Shareholder CVR Arbitration Total other expense, net Total other expense, net Nonoperating Income (Expense) Outstanding related-party warrants Related Party Warrants [Member] Related Party Warrants 2029 Lessee, Lease Liability, to be Paid, Year Three Lessee, Lease Liability, to be Paid, Year Three Reimbursements Reimbursements [Member] Reimbursements. ASSETS Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Operating lease liabilities Present value of lease liabilities Operating Lease, Liability Insider Trading Policies and Procedures [Line Items] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Present value of lease liabilities Finance Lease, Liability Allowances for prompt payment discounts, product returns and chargebacks Accounts Receivable, Allowance for Credit Loss, Current Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Selling, general and administrative Selling, general and administrative (including amounts with related parties) Selling, General and Administrative Expense Promissory Note Promissory Notes Payable [Member] Promissory Notes Payable Registered Direct Offering Private Placement [Member] Term without written consent Lessee, Operating Lease, Term Without Written Prior Consent Lessee, Operating Lease, Term Without Written Prior Consent Unpaid offering costs included in accounts payable and accrued expenses Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses Unpaid offering costs included in accounts payable and accrued expenses. Principal payments on premium financing Repayments of Debt Business Combination Business Combination [Domain] Required purchase price, as a percent Revenue Interest Purchase Agreement, Percentage of Cumulative Purchaser Payments, Repurchase Price Revenue Interest Purchase Agreement, Percentage of Cumulative Purchaser Payments, Repurchase Price Option Period [Domain] Option Period [Domain] Option Period [Domain] Forfeited/expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Number of operating segments Number of Operating Segments Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Estimated liability Estimated Litigation Liability RSUs Outstanding RSUs Restricted Stock Units (RSUs) [Member] Summary of Securities Excluded from the Computation of Potentially Dilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Other Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Business Combination Business Combination [Axis] Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] License Agreement Research, Development, and Computer Software Disclosure [Text Block] Net cash used in operating activities Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation 2031 Lessee, Lease Liability, to be Paid, Year Five Lessee, Lease Liability, to be Paid, Year Five 2026 (excluding the six months ended June 30, 2026) Long-Term Debt, Maturity, Remainder of Fiscal Year Income Statement [Abstract] Income Statement [Abstract] Stockholders’ deficit: Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Interest and investment income, net Gain (Loss) on Investments Cumulative purchaser payments Revenue Interest Purchase Agreement, Cumulative Purchaser Payments Revenue Interest Purchase Agreement, Cumulative Purchaser Payments Non-cash interest expense related to revenue interest liability Interest Expense, Nonoperating, Secured Debt, Net Interest Expense, Nonoperating, Secured Debt, Net Operating costs and expenses Operating Expenses [Abstract] Finance lease liabilities Finance Lease, Liability, Noncurrent Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Interest rate spread Debt Instrument, Basis Spread on Variable Rate Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Axis] Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Axis] Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule City Area Code City Area Code April 2025 Warrants April 2025 Warrants [Member] April 2025 Warrants Total future minimum lease payments Finance Lease, Liability, to be Paid Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] December 2024 Convertible Promissory Note December 2024 Convertible Promissory Note [Member] December 2024 Convertible Promissory Note All Individuals All Individuals [Member] Subsequent Event Subsequent Events [Text Block] Non-cash lease expense related to operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Expected average volatility Expected volatility Measurement Input, Price Volatility [Member] Contingent Value Rights Payable, Sales Milestone Contingent Value Rights Obligation, Sales Milestone [Member] Contingent value rights obligation before December 31, 2026. Schedule of Revenue by Geographic Region Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue [Table Text Block] Name Forgone Recovery, Individual Name Related-party convertible note Related Party, Convertible Note [Member] Related Party, Convertible Note Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Finished goods Inventory, Finished Goods, Net of Reserves Research and Development [Abstract] Research and Development [Abstract] Weighted-average period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted- Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Inventory on hand Inventory, On Hand Expensed Prior to FDA Approval Inventory, On Hand Expensed Prior to FDA Approval Statement [Line Items] Statement [Line Items] Total assets Assets Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Entity Entity [Domain] Annual lease payment Lease, Operating Lease, Annual Lease Payment Lease, Operating Lease, Annual Lease Payment 2028 Lessee, Lease Liability, to be Paid, Year Two Lessee, Lease Liability, to be Paid, Year Two Sale of stock, additional purchase option Sale Of Stock, Additional Purchase Option Sale Of Stock, Additional Purchase Option Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Stock Purchase And Option Agreement Stock Purchase And Option Agreement [Member] Stock Purchase And Option Agreement Net unrealized losses on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Summary of Stock-Based Compensation Expense Included on Statements of Operations Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Equipment, depreciation, and facility costs Research and Development Expense, Internal, Equipment, Depreciation, and Facility Costs Research and Development Expense, Internal, Equipment, Depreciation, and Facility Costs Third Payment Third Payment [Member] Third Payment Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Description of Business Nature of Operations [Text Block] Issuance of common stock/equity offering, net of commissions and offering costs (in shares) Shares issued (in shares) Stock Issued During Period, Shares, New Issues Accrued expenses and other liabilities Accrued rebates, co-payment assistance and other fees Accounts Payable and Other Accrued Liabilities, Current PEO PEO [Member] Interest expense recognized Interest Expense, Other Long-Term Debt Stock-based compensation expense Share-Based Payment Arrangement, Expense Repurchase of common stock, shares (in shares) Stock Repurchased and Retired During Period, Shares Marketable securities Marketable Securities, Current Other liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Thereafter Finance Lease, Liability, to be Paid, after Year Five Subsequent Event Type [Domain] Subsequent Event Type [Domain] Accumulated Deficit Retained Earnings [Member] Operating lease liabilities, less current portion Operating Lease, Liability, Noncurrent Total operating costs and expenses Operating Expenses Forfeited/canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Headcount hiring target Lease, Operating Lease, Headcount Hiring Target Lease, Operating Lease, Headcount Hiring Target Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Schedule of Unobservable Assumptions Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Increase (Decrease) in Statements of Stockholders’ Deficit [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Debt issuance costs Payments of Debt Issuance Costs Net loss per ImmunityBio common share - diluted (in dollars per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Net share settlement for RSUs vesting Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets February 2023 Warrants February 2023 Warrants [Member] February 2023 Warrants Unrealized losses on marketable debt securities, net Unrealized Gain (Loss) on Investments Litigation Case [Domain] Litigation Case [Domain] Write-off of convertible note receivable Write-Off Of Convertible Notes Receivable Write-Off Of Convertible Notes Receivable External research and development expense (including amounts with related parties) Research and Development Expense, External Research and Development Expense, External Less: Interest Lessee, Lease Liability, Undiscounted Excess Amount Lessee, Lease Liability, Undiscounted Excess Amount Research and development Research and development expense Total research and development expense (including amounts with related parties) Research and Development Expense Interest Payments Related Party Notes - Interest [Member] Related Party Notes - Interest Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Exercise of warrants (in shares) Stock Issued During Period, Shares, Warrants Exercised Stock Issued During Period, Shares, Warrants Exercised Financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Property, plant and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Option Period [Axis] Option Period [Axis] Option Period Revenue Interest Purchase Agreement [Abstract] Revenue Interest Purchase Agreement Revenue interest payment Debt Instrument, Periodic Payment, Interest Due to and due from related parties, net Increase Decrease In Due To Related Parties Current And Non Current Increase decrease in due to related parties current and non current. Options, Excluding Stock Purchase and Option Agreement Options, Excluding Stock Purchase and Option Agreement [Member] Options, Excluding Stock Purchase and Option Agreement Remaining Contractual Maturities (in years) Debt Securities, Available-for-Sale, Term Total internal research and development expense Research and Development Expense, Internal Research and Development Expense, Internal Financial Instruments Financial Instruments [Domain] Change in Fair Value of Derivative Liabilities Schedule of Derivative Liabilities at Fair Value [Table Text Block] Vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Inventories Inventory Disclosure [Text Block] Annual operating spending Leasehold Interest, Operational Expenses, Annual Operating Spending, Minimum Leasehold Interest, Operational Expenses, Annual Operating Spending, Minimum Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Tiered Payments [Axis] Tiered Payments [Axis] Tiered Payments Less: Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Revenues Revenue from Contract with Customer [Text Block] Issuance of common stock/equity offering, net of commissions and offering costs Stock Issued During Period, Value, New Issues Additional merger consideration (in dollar per share) Business Acquisition, Additional Merger Consideration Business Acquisition, Additional Merger Consideration Available for future stock issuance Sale of Stock, Amount Available For Future Stock Issuance Sale of Stock, Amount Available For Future Stock Issuance ATM, amount available for future issuances Sale of Stock Offering, Amount Available for Future Issuance Sale of Stock Offering, Amount Available for Future Issuance Inventories Increase (Decrease) in Inventories Debt converted, shares issued (in shares) Debt Conversion, Converted Instrument, Shares Issued Weighted average discount rate, operating leases Operating Lease, Weighted Average Discount Rate, Percent Summary of RSU Activity under Equity Plans Nonvested Restricted Stock Shares Activity [Table Text Block] Segment Reporting [Table] Segment Reporting [Table] Common stock reserved for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Issuance of common stock upon vesting of RSUs Stock Issued Summary of Future Contractual Obligations of Related Party Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Table] Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value. Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Sale of Stock Sale of Stock [Axis] Weighted- Average Remaining Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Summary of Information Regarding Leases Lease, Cost [Table Text Block] Contingent consideration Business Combination, Contingent Consideration, Liability, Current Summary of Available-for-Sale Marketable Debt Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Impairment of intangible assets Other Nonoperating Income (Expense) [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Fair value, beginning of period Fair value, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Less than 12 months, Estimated Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Change in fair value of derivative liabilities Derivative, Gain (Loss) on Derivative, Net Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Operating Income (Loss) Immuno-Oncology Clinic, Inc. Immuno-Oncology Clinic, Inc [Member] Immuno Oncology Clinic Inc. Current Fiscal Year End Date Current Fiscal Year End Date Summary of Future Minimum Lease Payments, Finance Finance Lease, Liability, to be Paid, Maturity [Table Text Block] 2026 (excluding the six months ended June 30, 2026) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Warrant liabilities Warrants and Rights Outstanding Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Related Party Transaction Related Party Transaction [Domain] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Commitment to spend, operational expenses, renewal lease term Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Stockholders' Equity Note, Warrants or Rights Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of Stock Option Activity under Equity Plans Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Total lease liabilities (including amounts with related parties) Lessee, Lease Liability Lessee, Lease Liability Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Cash Flow Operating Activities Lessee [Abstract] Cash Flow, Operating Activities, Lessee [Abstract] Annual minimum licensing payment Collaboration Agreements, Annual Minimum Licensing Payment Collaboration Agreements, Annual Minimum Licensing Payment Treasury stock, common shares (in shares) Treasury Stock, Common, Shares NantWorks NantWorks, LLC [Member] NantWorks, LLC U.S. Treasury securities Debt Securities, Available-for-Sale, Current More than 12 months, Gross Unrealized Losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Equity Components [Axis] Equity Components Equity Components [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Related-Party Related Party [Member] Class Of Stock [Line Items] Class of Stock [Line Items] Income taxes Income Tax Paid, after Refund Received Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Settlement interest Litigation Settlement Interest Entity Interactive Data Current Entity Interactive Data Current Finance lease liabilities Finance Lease, Liability, Current Net loss attributable to noncontrolling interests, net of tax Net Income (Loss) Attributable to Noncontrolling Interest Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Warrants Warrants [Member] Warrants. Licensing Agreement [Table] Licensing Agreement [Table] Licensing agreement. Reclassification of net realized gains on available-for-sale securities included in net loss Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Entity Small Business Entity Small Business Comprehensive loss attributable to ImmunityBio common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Second Largest Customer Second Largest Customer [Member] Second Largest Customer Upfront payment received Upfront Payment Received Upfront Payment Received 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Termination Date Trading Arrangement Termination Date Net share settlement for RSUs vesting (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Accounts payable Increase (Decrease) in Accounts Payable, Trade Subsequent Events [Abstract] Warrant exercises Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other assets Other Assets, Noncurrent 2029 Finance Lease, Liability, to be Paid, Year Three Document Type Document Type Contingent Value Rights Obligation, Regulatory Milestone Contingent Value Rights Obligation, Regulatory Milestone [Member] Contingent Value Rights Obligation, Regulatory Milestone Fair Value as of Grant Date Award Grant Date Fair Value Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Convertible note receivable Convertible Note Receivable Non Current Convertible note receivable, non-current. Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Remaining authorized repurchase amount Share Repurchase Program, Remaining Authorized, Amount Arrangement Duration Trading Arrangement Duration Subsequent Event [Line Items] Subsequent Event [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Aggregate intrinsic value, vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Less than 12 months, Gross Unrealized Losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Fair value of warrants Warrants Not Settleable in Cash, Fair Value Disclosure Accrued Rebates, Co-payment Assistance and Other Fees Accrued Rebates, Co-payment Assistance and Other Fees [Member] Accrued Rebates, Co-payment Assistance and Other Fees Loss before income taxes and noncontrolling interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Total future minimum lease payments Lessee, Lease Liability, to be Paid Lessee, Lease Liability, to be Paid Interest expense related to revenue interest liability Interest expense related to revenue interest liability Interest Expense, Other Commitments and Contingencies (Note 8) Commitments and Contingencies Total segment revenue Revenues Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Common stock, value available for future stock issuance Common Stock Value Available For Future Stock Issuance Common stock value available for future stock issuance. Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Measurement input Warrants and Rights Outstanding, Measurement Input Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Total assets Liabilities and Equity [Abstract] Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Change in Fair Value of Stock Option Purchase Liability Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Inventories Inventory, Net Award Type Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Equity Method Investment, Nonconsolidated Investee Equity Method Investment, Nonconsolidated Investee, Other [Member] Warrants outstanding, beginning of period (in shares) Warrants outstanding, end of period (in shares) Number of warrants outstanding (in shares) Number of warrants outstanding (in shares) Class of Warrant or Right, Outstanding 2026 (excluding the six months ended June 30, 2026) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Level 3 Fair Value, Inputs, Level 3 [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Transaction Type Transaction Type [Axis] Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term Initial term of lease arrangement Lessee, Operating Lease, Term of Contract Dunkirk Facility Dunkirk Facility [Member] Dunkirk Facility PEO Name PEO Name Geographical Geographical [Axis] Summary of Related-Party Debt Schedule of Related-Party Promissory Notes Table [Table Text Block] Schedule of related party notes payable. Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Legal Entity Legal Entity [Axis] Interest expense Interest expense on related-party notes payable Interest Expense, Debt Related-party convertible note payable, at fair value Convertible Notes Payable, Noncurrent Lessee Lease Description [Table] Lessee, Lease, Description [Table] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Total Lease Liability, Payments Due [Abstract] Lease Liability, Payments Due Reportable Segment Reportable Segment [Member] Reportable Segment Largest Customer Largest Customer [Member] Largest Customer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Initial Payment Initial Payment [Member] Initial Payment Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 18 to 36 Months From Closing Date Period Three [Member] Period Three Debt Instrument [Axis] Debt Instrument [Axis] Subsequent Event [Table] Subsequent Event [Table] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Conversion of related-party convertible notes (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Customer [Domain] Customer [Domain] Statement of Inventories Schedule of Inventory, Current [Table Text Block] Lease Arrangements Lessee, Operating Leases [Text Block] 2027 Long-Term Debt, Maturity, Year One Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Net loss per ImmunityBio common share – basic (in dollars per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Risk-free interest rate Measurement Input, Risk Free Interest Rate [Member] Total current assets Assets, Current Statistical Measurement Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Principal Payments Related Party Notes - Principal [Member] Related Party Notes - Principal Prepayment and accrued interest upon specified transaction Debt Instrument, Prepayment And Accrued Interest Debt Instrument, Prepayment And Accrued Interest Award Type Award Type [Axis] Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain] Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain] Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain] Summary of Revenue Interest Liability Activity Summarizes the Revenue Interest Liability Activity [Table Text Block] Summarizes the Revenue Interest Liability Activity Payments of Financing Costs Payments of Financing Costs Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Restricted cash Restricted Cash, Noncurrent Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Proceeds from the RIPA, net of issuance costs Proceeds from Third Payment, net of issuance costs Proceeds from Issuance of Secured Debt Common Stock Common Stock [Member] Fair Value Debt Securities, Available-for-Sale Headcount hiring target, exercise option Lease, Operating Lease, Headcount Hiring Target, Exercise Option Lease, Operating Lease, Headcount Hiring Target, Exercise Option Expected market yield Measurement Input, Market Yield [Member] Measurement Input, Market Yield Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Within 12 Months of Closing Date Period One [Member] Period One Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Concentration risk, percentage Concentration Risk, Percentage Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Equity Awards Adjustments Equity Awards Adjustments [Member] $505 Million Promissory Note, December 2023, Tranche 1 $505 Million Promissory Note, December 2023, Tranche 1 [Member] $505 Million Promissory Note, December 2023, Tranche 1 Related Party Notes Related Party Notes [Member] Related Party Notes Purchase price allocation Sale Of Stock And Revenue Interest Purchase Agreement, Consideration Received On Transaction Sale Of Stock And Revenue Interest Purchase Agreement, Consideration Received On Transaction Total liabilities and stockholders’ deficit Liabilities and Equity 2022 Collaborative Arrangement and Arrangement Other than Collaborative, Fee One [Member] Collaborative Arrangement and Arrangement Other than Collaborative, Fee One Goodwill and intangible assets, net Intangible Asset, Including Goodwill, after Accumulated Amortization Stock options Outstanding stock options Share-Based Payment Arrangement, Option [Member] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Personnel-related costs Research and Development Expense, Internal, Personnel-related Costs Research and Development Expense, Internal, Personnel-related Costs Plan Name Plan Name [Axis] Related Party Related and Nonrelated Parties [Domain] Operating lease payments related to options to extend lease terms Operating Lease Payments Related To Options To Extend Lease Terms Operating lease payments related to options to extend lease terms. Stock option liability, measurement input Derivative Liability, Measurement Input Inventory Disclosure [Abstract] Reclassification of realized gain on instrument-specific credit risk Reclassification of change in fair value related to instrument-specific credit risk Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, Reclassification Adjustment from AOCI for Derecognition, after Tax Tabular List, Table Tabular List [Table Text Block] Restricted cash (included in Other Assets) Restricted Cash and Cash Equivalent, Noncurrent Other income (expense), net Other income (expense), net Other Nonoperating Income (Expense) Total ImmunityBio Stockholders’ Deficit Parent [Member] Name Awards Close in Time to MNPI Disclosures, Individual Name Change in fair value of related-party convertible note Increase (Decrease) in Fair Value, Long-Term Debt Increase (Decrease) in Fair Value, Long-Term Debt Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Outstanding, beginning balance Outstanding, ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Forfeited/canceled (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Sale of stock (in dollars per share) Sale of Stock, Price Per Share Conversion of related-party convertible note Stock Issued During Period, Value, Conversion of Convertible Securities Cumulative capital spending Leasehold Interest, Operational Expenses, Cumulative Capital Spending, Minimum Leasehold Interest, Operational Expenses, Cumulative Capital Spending, Minimum Business Combination, Contingent Consideration, Type Business Combination, Contingent Consideration, Type [Domain] Measurement input Debt Instrument, Measurement Input Fair Value of Warrants, Carrying Amount [Roll Forward] Fair Value of Warrants, Carrying Amount [Roll Forward] Fair Value of Warrants, Carrying Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Accrued expenses and other liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Revenue interest purchase agreement, tiered revenue interest rate percentage Revenue Interest Purchase Agreement, Tiered Revenue Interest Rate Percentage Revenue Interest Purchase Agreement, Tiered Revenue Interest Rate Percentage Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Operating cash flow from finance leases Finance Lease, Interest Payment on Liability Interest Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total assets measured at fair value Assets, Fair Value Disclosure 2031 Finance Lease, Liability, to be Paid, Year Five 3M IPC and AAHI License Agreement 3M IPC and AAHI Agreement [Member] 3M IPC and AAHI Agreement Name Measure Name Second Payment Second Payment [Member] Second Payment Income Taxes Income Tax Disclosure [Text Block] Accounts payable Total due to related parties Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Non-cash interest items, net Other Noncash Income (Expense) 2031 Lessee, Operating Lease, Liability, to be Paid, Year Five Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Business combination, consideration transferred Business Combination, Consideration Transferred Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category 2023 and 2025 Warrants 2023 and 2025 Warrants [Member] 2023 and 2025 Warrants Software development costs Payments to Develop Software Name Trading Arrangement, Individual Name Unrecognized compensation cost related to non-vested stock options Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Cash and cash equivalents Cash and Cash Equivalent Expected term Measurement Input, Expected Term [Member] Finance Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Lease expense Operating Lease, Expense Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Company Selected Measure Amount Company Selected Measure Amount Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Table Text Block] Transaction costs allocated to warrant liabilities Transaction Costs, Warrant Liability Transaction Costs, Warrant Liability Minimum net sales milestone for contingent value rights payable Minimum Net Sales Milestone Contingent Value Rights Obligation Minimum net sales milestone contingent value rights obligation. Dr. Soon-Shiong and Related Party Dr Soon-Shiong And Related Party [Member] Dr. Soon-Shiong and related party. Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Inventories Inventory, Gross Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Right-of-use assets obtained in exchange for finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Current assets: Assets, Current [Abstract] Weighted average remaining lease term, operating leases Operating Lease, Weighted Average Remaining Lease Term Change in fair value of related-party convertible note related to instrument-specific credit risk Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, Unrealized Gain (Loss) Arising During Period, after Tax RIPA derivative liabililty Derivative Liability Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Income tax expense Income tax expense (benefit) Income tax expense Income Tax Expense (Benefit) Customer Concentration Risk Customer Concentration Risk [Member] Convertible Note Convertible Notes Payable [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Cost of sales Cost of Product and Service Sold Award Timing Method Award Timing Method [Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Net change in cash and cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Other revenues Product and Service, Other [Member] Forecast Forecast [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] NantWorks NantWorks [Member] NantWorks. Net loss attributable to ImmunityBio common stockholders Net Income (Loss) Attributable to Parent Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Private Placement and At the Market Offerings Private Placement and At the Market Offerings [Member] Private Placement and At the Market Offerings [Member] Statement [Table] Statement [Table] Top Four Customers Top Four Customers [Member] Top Four Customers Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Restatement Determination Date: Restatement Determination Date [Axis] Proceeds from exercises of stock options Proceeds from stock options exercised Proceeds from Stock Options Exercised Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Conversion of related-party convertible note into equity Debt Conversion, Converted Instrument, Amount Licensing Agreement [Line Items] Licensing Agreement [Line Items] Licensing agreement. Proceeds from borrowings Proceeds from Short-Term Debt Change in fair value of related-party convertible note Change in fair value of related-party convertible note Fair Value, Option, Changes in Fair Value, Gain (Loss) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block]